Patents by Inventor Connie HONG
Connie HONG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240134914Abstract: A method identifies related data visualizations. A computing device displays a data visualization according to a data source. The data visualization displays of one or more first data fields from the data source, and is displayed according to one or more first metadata fields. The device identifies a collection of predefined data visualizations for the data source. For each element in the collection, the device computes a respective ranking according to a plurality of influence scores, each influence score computed according to comparing data fields and metadata fields of the respective predefined data visualization to the one or more first data fields and the one or more associated first metadata fields. The device then selects a subset of the predefined data visualizations that have top ranking and provides an ordered list of the selected subset, including at least one influence score for each included data visualization.Type: ApplicationFiled: January 2, 2024Publication date: April 25, 2024Inventors: Connie Hong-Ying WONG, Xiangbo MAO, Kazem JAHANBAKHSH, Eric Roy BROCHU
-
Patent number: 11952428Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.Type: GrantFiled: February 17, 2023Date of Patent: April 9, 2024Assignee: Novartis AGInventors: Aida Abujoub, John Blankenship, Dexiu Bu, Tony Fleming, Brian Holmberg, Connie Hong, Lu Huang, Chonghui Zhang
-
Patent number: 11939389Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.Type: GrantFiled: February 17, 2023Date of Patent: March 26, 2024Assignee: Novartis AGInventors: Aida Abujoub, John Blankenship, Dexiu Bu, Tony Fleming, Brian Holmberg, Connie Hong, Lu Huang, Chonghui Zhang
-
Publication number: 20230416390Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.Type: ApplicationFiled: March 16, 2023Publication date: December 28, 2023Inventors: Aida Abujoub, John Blankenship, Dexiu Bu, Tony Fleming, Brian Holmberg, Connie Hong, Lu Huang, Chonghui Zhang
-
Publication number: 20230295322Abstract: The present disclosure provides BCMA binding molecules that specifically bind to human BCMA, conjugates comprising the BCMA binding molecules, and pharmaceutical compositions comprising the BCMA binding molecules and the conjugates. The disclosure further provides methods of using the BCMA binding molecules to treat cancers that express cell surface BCMA. The disclosure yet further provides recombinant host cells engineered to express the BCMA binding molecules and methods of producing the BCMA binding molecules by culturing the host cells under conditions in which the BCMA binding molecules are expressed.Type: ApplicationFiled: September 21, 2022Publication date: September 21, 2023Applicant: NOVARTIS AGInventors: Aida ABUJOUB, John BLANKENSHIP, Tony FLEMING, Brian HOLMBERG, Connie HONG, Lu HUANG, Haihui LU
-
Publication number: 20230250179Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.Type: ApplicationFiled: February 17, 2023Publication date: August 10, 2023Inventors: Aida Abujoub, John Blankenship, Dexiu Bu, Tony Fleming, Brian Holmberg, Connie Hong, Lu Huang, Chonghui Zhang
-
Publication number: 20230183368Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.Type: ApplicationFiled: February 17, 2023Publication date: June 15, 2023Inventors: Aida Abujoub, John Blankenship, Dexiu Bu, Tony Fleming, Brian Holmberg, Connie Hong, Lu Huang, Chonghui Zhang
-
Patent number: 11608382Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.Type: GrantFiled: June 12, 2019Date of Patent: March 21, 2023Assignee: Novartis AGInventors: Aida Abujoub, John Blankenship, Dexiu Bu, Tony Fleming, Brian Holmberg, Connie Hong, Lu Huang, Chonghui Zhang
-
Publication number: 20230071196Abstract: The present disclosure provides CD2 binding molecules that specifically bind to CD2, including monospecific, bispecific and trispecific binding molecules, conjugates comprising the CD2 binding molecules, and pharmaceutical compositions comprising the CD2 binding molecules and the conjugates. The disclosure further provides methods of using the CD2 binding molecules to modulate CD2 signaling in order to treat a variety of immune (e.g., autoimmune), inflammatory and proliferative disorders. The disclosure yet further provides recombinant host cells engineered to express the CD2 binding molecules and methods of producing the CD2 binding molecules by culturing the host cells under conditions in which the CD2 binding molecules are expressed.Type: ApplicationFiled: May 19, 2020Publication date: March 9, 2023Inventors: Barbara BRANNETTI, Dattananda CHELUR, Brian GRANDA, Connie HONG
-
Publication number: 20220396631Abstract: The present disclosure provides multispecific binding molecules that specifically bind to BCMA, a component of a human T-cell receptor complex and either CD2 or a tumor associated antigen, conjugates comprising the multispecific binding molecules, and pharmaceutical compositions comprising the multispecific binding molecules and the conjugates The disclosure further provides methods of using the multispecific binding molecules to treat disease and disorders associated with expression of BCMA. The disclosure yet further provides recombinant host cells engineered to express the multispecific binding molecules and methods of producing the multispecific binding molecules by culturing the host cells under conditions in which the multispecific binding molecules are expressed.Type: ApplicationFiled: May 19, 2020Publication date: December 15, 2022Inventors: Brian Walter Granda, John Blankenship, Aida Abujoub, Tony Fleming, Lu Huang, Connie Hong, Brian Holmberg, Haihui Lu
-
Publication number: 20220364055Abstract: The invention provides methods of making immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions generated by such methods.Type: ApplicationFiled: August 30, 2019Publication date: November 17, 2022Inventors: Louise Treanor, Michael R. Greene, Jennifer Brogdon, Boris Engels, Glenn Dranoff, Olja Kodrasi, Hyungwook Lim, Akash Sohoni, Elizabeth Dorothy Pratico, Anniesha Hack, Aida Abujoub, Tony Fleming, Lu Huang, Connie Hong, John Blankenship, Brian Holmberg, Chonghui Zhang, Dexiu Bu, Andrew Price, Xu Zhu, Andrew Stein, Attilio Bondanza
-
Patent number: 11492409Abstract: The present disclosure provides BCMA binding molecules that specifically bind to human BCMA, conjugates comprising the BCMA binding molecules, and pharmaceutical compositions comprising the BCMA binding molecules and the conjugates. The disclosure further provides methods of using the BCMA binding molecules to treat cancers that express cell surface BCMA. The disclosure yet further provides recombinant host cells engineered to express the BCMA binding molecules and methods of producing the BCMA binding molecules by culturing the host cells under conditions in which the BCMA binding molecules are expressed.Type: GrantFiled: May 30, 2019Date of Patent: November 8, 2022Assignee: Novartis AGInventors: Aida Abujoub, John Blankenship, Tony Fleming, Brian Holmberg, Connie Hong, Lu Huang, Haihui Lu
-
Publication number: 20220332821Abstract: The present disclosure relates to dosing regimens, formulations, and combinations comprising a multispecific antibody having at least binding specificity towards B cell maturation antigen (BCMA) and a T-cell engaging arm; and methods of using such multispecific antibodies in the treatment or prevention of disease, such as, cancer.Type: ApplicationFiled: June 22, 2020Publication date: October 20, 2022Inventors: Kimberly AARDALEN, Aida ABUJOUB, John BLANKENSHIP, Anuradha CONNOR, Mirek DOSTALEK, Tony FLEMING, Brian HOLMBERG, Connie HONG, Lu HUANG, Haihui LU, K. Gary J. VANASSE
-
Publication number: 20220237229Abstract: Embodiments are directed to managing visualizations of data. A visualization associated with one or more community visualizations that are associated with an organization may be displayed. A recommendation score may be generated for each of the community visualizations based on a comparison of meta-data fields. Top ranked community visualizations may be determined based on the recommendation score associated with each of the community visualizations. An influence score may be determined the meta-data fields based on a proportion of a value each meta-data field contributes to the recommendation score of a corresponding top ranked community visualization. A report that includes a rank ordered list of the top ranked community visualizations and the top ranked other meta-data fields may be provided to the user.Type: ApplicationFiled: January 26, 2021Publication date: July 28, 2022Inventors: Connie Hong-Ying Wong, Xiangbo Mao, Kazem Jahanbakhsh, Eric Roy Brochu
-
Publication number: 20210220404Abstract: The invention provides immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions and methods thereof.Type: ApplicationFiled: November 25, 2020Publication date: July 22, 2021Inventors: Aida Abujoub, John Blankenship, Attilio Bondanza, Jennifer Brogdon, Dexiu Bu, Serena De Vita, Glenn Dranoff, Boris Engels, Tony Fleming, Brian Walter Granda, Michael R. Greene, Carla Patricia Guimaraes, Anniesha Hack, Brian Holmberg, Connie Hong, Lu Huang, Olja Kodrasi, Joni Waiee Lam, Hyungwook Lim, Elizabeth Dorothy Pratico, Andrew Price, Akash Sohoni, Andrew Marc Stein, Louise Treanor, Chonghui Zhang, Xu Zhu
-
Publication number: 20210163620Abstract: The present disclosure provides multispecific binding molecules that specifically bind to a first tumor-associated antigen that is expressed on cancerous B cells, a second tumor-associated antigen that is expressed on cancerous B cells, and a component of a human T-cell receptor complex, conjugates comprising the trispecific binding molecules, and pharmaceutical compositions comprising the multispecific binding molecules and the conjugates. The disclosure further provides methods of using the multispecific binding molecules to treat cancers that express the tumor-associated antigens. The disclosure yet further provides recombinant host cells engineered to express the multispecific binding molecules and methods of producing the multispecific binding molecules by culturing the host cells under conditions in which the multispecific binding molecules are expressed.Type: ApplicationFiled: April 4, 2019Publication date: June 3, 2021Inventors: Brian GRANDA, Connie HONG
-
Publication number: 20210139585Abstract: The present disclosure provides CD19 binding molecules that specifically bind to CD19, including monospecific, bispecific and trispecific binding molecules, conjugates comprising the CD19 binding molecules, and pharmaceutical compositions comprising the CD19 binding molecules and the conjugates. The disclosure further provides methods of using the C19 binding molecules to treat diseases and disorders associated with expression of CD19. The disclosure yet further provides recombinant host cells engineered to express the CD19 binding molecules and methods of producing the CD19 binding molecules by culturing the host cells under conditions in which the CD19 binding molecules are expressed.Type: ApplicationFiled: May 19, 2020Publication date: May 13, 2021Applicant: Novartis AGInventors: Brian Granda, Amy Rayo, Connie Hong, Dattananda Chelur, Haihui Lu, Regis Cebe, Sunyoung Jang
-
Publication number: 20210133239Abstract: Embodiments are directed to managing visualizations of data. Visualization models and a user profile may be provided such that the visualization models and the user profile may be associated with an organization. A complexity score for the organization may be provided based on one or more characteristics of the organization. A recommendation model may be provided based on the complexity score and a baseline model. The recommendation model may be employed to determine one or more recommended visualization models based on the user profile such that the recommendation model associates each recommended visualization model with a confidence score. The one or more recommended visualization models may be rank ordered based on each associated confidence score. A report that includes a rank ordered list of the one or more recommended visualization models may be provided to a user associated with the user profile.Type: ApplicationFiled: November 1, 2019Publication date: May 6, 2021Inventors: Eric Roy Brochu, Mya Rose Warren, Yogesh Sood, David John Mosimann, Connie Hong-Ying Wong, Kazem Jahanbakhsh
-
Publication number: 20200362054Abstract: The present disclosure provides trispecific binding molecules that specifically bind to CD2, CD3 and a tumor-associated antigen, conjugates comprising the trispecific binding molecules, and pharmaceutical compositions comprising the trispecific binding molecules and the conjugates. The disclosure further provides methods of using the trispecific binding molecules to treat cancers that express the tumor-associated antigens. The disclosure yet further provides recombinant host cells engineered to express the trispecific binding molecules and methods of producing the trispecific binding molecules by culturing the host cells under conditions in which the trispecific binding molecules are expressed.Type: ApplicationFiled: November 20, 2018Publication date: November 19, 2020Inventors: Brian GRANDA, Connie HONG, Melissa RAMONES, Darko SKEGRO
-
Publication number: 20190382500Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.Type: ApplicationFiled: June 12, 2019Publication date: December 19, 2019Inventors: Aida Abujoub, John Blankenship, Dexiu Bu, Tony Fleming, Brian Holmberg, Connie Hong, Lu Huang, Chonghui Zhang